Joint bleeding is the most common bleeding manifestation of hemophilia, accounting for about 70-80% of all bleeding manifestations, with the knee joint being the most commonly involved (about 45%). Repeated bleeding in the joints can easily lead to hemophilic arthritis, which is generally divided into 3 phases: acute joint bleeding phase, chronic synovitis phase, and degenerative arthritis phase. Acute joint bleeding can induce an inflammatory response and hyperplasia of the synovial membrane. The hyperplastic synovial membrane and blood vessels are more fragile, and minor injuries can easily lead to rebleeding. Therefore, once the first bleeding occurs in a joint, it will easily enter the vicious cycle of bleeding, synovial hyperplasia, and bleeding again, gradually developing into chronic synovitis. Chronic synovitis is characterized by persistent swelling of the joint and atrophy of the muscles around the joint. If not treated in a timely manner, chronic synovitis lasting more than 6 months can cause degenerative changes in the joint, resulting in articular cartilage and subchondral bone tissue lesions, superficial bone tissue defects, subchondral cystic changes, osteoporosis, uneven joint surfaces, and the initial fragile congested tissue on the synovial surface gradually evolving into fibrous scar tissue, resulting in different degrees of disability. In patients with early intra-articular hemorrhage, the conventional treatment is to supplement the lack of coagulation factors (replacement therapy) and first-aid measures (ice, braking, compression bandages, elevation of the affected limb, etc.), which can reduce intra-articular hemorrhage and slow down or even stop the progression of hemophilic arthritis. However, patients with heavy bleeding or untimely treatment have difficulty achieving the desired outcome. In addition, the short half-life of coagulation factors and their high price make the optimal start and termination times of therapy as well as the selection and targeting of therapeutic doses a major issue in alternative treatment. In general, continuous prophylactic supplementation of clotting factors is difficult to achieve; braking can shorten the joint capsule, ligaments, and muscle tendons around the joints on the one hand, resulting in decreased joint mobility, and also atrophy of the muscles around the joints, reduced ligament strength, and decreased proprioceptive function, which can easily damage joint structures and increase the chance of bleeding during activity. In the past, medical practitioners in China had misconceptions about the rehabilitation of hemophilia, believing that hemophilia is a bleeding disease and physiotherapy can easily induce and aggravate bleeding. Therefore, physiotherapy is a contraindication. Patients who cannot regain motor function in a short period of time through conventional treatment naturally enter into long-term braking, resulting in muscle atrophy, tendon contracture, joint stiffness, synovial hyperplasia, decreased proprioception, and easy rebleeding, which repeatedly leads to different degrees of disability. In recent years, the application of physical factors in the treatment of hemophilic hemorrhage has been reported at home and abroad. It is believed that physical therapy combined with exercise therapy (comprehensive rehabilitation) can promote the absorption of hematoma, reduce the inflammatory reaction of synovium, enhance muscle strength and improve proprioceptive function, thus interrupting the vicious cycle and restoring motor function. Our experience also shows that comprehensive rehabilitation therapy (especially for mild to moderate patients) has a low chance of triggering hemophilia bleeding, and is actually safe and effective.